TP53 and cancer: Similar to the antibody response to ORF1p, the same patients with cancer showed a significantly higher elevation in anti-p53 versus healthy subjects [median, 514 (IQR, 321–826) vs. 437 (IQR, 232–614); P = 0.0004] (Fig. 1D; Supplementary Fig. S2C).